---
title: "BioNexus advances VitaGuard Southeast Asia rollout after China hospital visits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294070529.md"
description: "BioNexus advanced the Southeast Asia rollout of its VitaGuard MRD platform following working visits to Tongshu Gene facilities in Shanghai and Changzhou. Site visits to Chinese hospitals utilizing VitaGuard commercially support BioNexus's target for initial deployment in 2026."
datetime: "2026-07-28T13:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294070529.md)
  - [en](https://longbridge.com/en/news/294070529.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294070529.md)
---

# BioNexus advances VitaGuard Southeast Asia rollout after China hospital visits

-   BioNexus attended a working visit to Tongshu Gene facilities in Shanghai and Changzhou to advance the VitaGuard MRD platform rollout in Southeast Asia. \* Sessions mapped implementation needs, with site visits to Chinese hospitals using VitaGuard commercially supporting BioNexus’s 2026 initial deployment target. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280900PRIMZONEFULLFEED9799214) on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BGLC.US](https://longbridge.com/en/quote/BGLC.US.md)

## Related News & Research

- [Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates](https://longbridge.com/en/news/294255863.md)
- [TEM: Q2 2026 delivered 22% revenue growth, net income turnaround, and major MRD expansion via acquisition](https://longbridge.com/en/news/294408929.md)
- [Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease](https://longbridge.com/en/news/294682847.md)
- [Lauxera Capital Partners invests in GenePlanet in private funding round](https://longbridge.com/en/news/294314706.md)
- [Analyst Reaffirms Buy on Adaptive Biotechnologies, Lifting Price Target to $25 Amid Strong MRD Momentum and Raised 2026 Guidance](https://longbridge.com/en/news/294342713.md)